Xbrane Biopharma AB

Xbrane Biopharma AB is a Swedish biopharmaceutical company developing biosimilars to make expensive biological drugs accessible for treating serious diseases like cancer and macular degeneration. Headquartered in Solna, Sweden. Here are key aspects of the company:

• Products & Services: The company develops biosimilars specifically targeting macular degeneration (Xlucane™) and cancer (Xdivane™), utilizing a patented platform technology that claims up to 12 times productivity and an 80% cost reduction compared to standard systems.
• Customers & Industries Served: Their products address originator sales of over SEK 100 billion, focusing on patients affected by serious diseases such as cancer, rheumatoid arthritis, psoriasis, and macular degeneration.
• Innovation & Technology: Xbrane bases its development on patented platform technology designed to significantly lower the cost of producing biological drugs while increasing productivity. Xbrane Biopharma AB is known for leveraging proprietary platform technology to reduce costs and expand access to essential biosimilar treatments.